We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
-16.68%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$63B
AUM Growth
-$15.8B
Cap. Flow
-$523M
Cap. Flow %
-0.83%
Top 10 Hldgs %
24.77%
Holding
3,865
New
199
Increased
1,422
Reduced
1,761
Closed
372

Sector Composition

Rank Sector Weight
1 Technology 12.16%
2 Healthcare 9.23%
3 Financials 8.29%
4 Industrials 5.85%
5 Communication Services 5.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PXD
3726
CALL
DELISTED
Pioneer Natural Resource Co.
PXD
-10,800
Closed -$2K
KAMN
3727
DELISTED
Kaman Corp
KAMN
-3,113
Closed -$205K
MTBL
3728
DELISTED
Moatable, Inc. American Depositary Share (each representing forty-five (45) Class A Ordinary Shares)
MTBL
-98,733
Closed -$25K
CBAY
3729
DELISTED
Cymabay Therapeutics
CBAY
-11,059
Closed -$22K
CLRG
3730
DELISTED
IndexIQ ETF Trust IQ U.S. Large Cap ETF
CLRG
-27,494
Closed -$743K
CORR
3731
DELISTED
CorEnergy Infrastructure Trust, Inc.
CORR
-5,486
Closed -$245K
HEP
3732
DELISTED
Holly Energy Partners, L.P.
HEP
-10,433
Closed -$231K
ICPT
3733
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
-13,900
Closed -$111K
WWE
3734
DELISTED
World Wrestling Entertainment
WWE
-4,517
Closed -$293K
GLOP
3735
DELISTED
GASLOG PARTNERS LP
GLOP
-27,942
Closed -$437K
USX
3736
DELISTED
U.S. Xpress Enterprises, Inc. Class A Common Stock
USX
-15,000
Closed -$75K
BLCM
3737
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
-4,373
Closed -$56K
MAXR
3738
DELISTED
Maxar Technologies Inc. Common Stock
MAXR
-10,937
Closed -$171K
BBBY
3739
CALL
DELISTED
Bed Bath & Beyond Inc
BBBY
-32,300
Closed -$83K
CSII
3740
DELISTED
Cardiovascular Systems, Inc.
CSII
-5,261
Closed -$256K
IVH
3741
DELISTED
Delaware Ivy High Income Opportunities Fund
IVH
-10,561
Closed -$147K
CNCE
3742
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
-11,073
Closed -$102K
LCI
3743
DELISTED
Lannett Company, Inc.
LCI
-3,208
Closed -$113K
PRTY
3744
DELISTED
Party City Holdco Inc.
PRTY
-15,062
Closed -$35K
SNP
3745
DELISTED
CHINA PETROLEUM & CHEMICAL CORPORATION ADS (REP 100 ORDINARY H SHARES)
SNP
-5,580
Closed -$336K
PTR
3746
DELISTED
PETROCHINA COMPANY LIMITED ADS (REP 100 H SHARES)
PTR
-9,877
Closed -$497K
SAIL
3747
DELISTED
SailPoint Technologies Holdings, Inc. Common Stock
SAIL
-25,690
Closed -$606K
CNR
3748
DELISTED
Cornerstone Building Brands, Inc.
CNR
-56,068
Closed -$477K
HNP
3749
DELISTED
Huaneng Power Intl, Inc.
HNP
-10,008
Closed -$201K
TVTY
3750
DELISTED
Tivity Health, Inc. Common Stock
TVTY
-14,091
Closed -$287K

Similar funds

Raymond James & Associates's Q1 2020 Portfolio in Review

As of Q1 2020, Raymond James & Associates held 3,865 positions worth $63B, down 20% from $78.8B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Raymond James & Associates's Q1 2020 filing shows 199 new, 1,422 increased, 1,761 reduced and 372 closed positions. Its largest new stake was BlackRock Health Sciences Trust II: 570,215 shares worth $10.2M. The largest sale was Carnival Corporation Ltd, an estimated $106M.

By sector, the portfolio is most concentrated in Technology at 12% of assets, up from 11% a quarter earlier, followed by Healthcare and Financials.

  • Raymond James & Associates's largest Q1 2020 buy was BlackRock Health Sciences Trust II: 570,215 shares worth $10.2M.
  • Raymond James & Associates added most to iShares Core US Aggregate Bond ETF in Q1 2020, an estimated $220M increase.
  • Raymond James & Associates's biggest Q1 2020 reduction was Carnival Corporation Ltd, cutting an estimated $106M.
  • Raymond James & Associates fully exited State Street SPDR Portfolio S&P 400 Mid Cap ETF in Q1 2020, selling an estimated $36.8M.
  • Raymond James & Associates's ten largest holdings make up 25% of its $63B portfolio in Q1 2020.
  • Raymond James & Associates opened 199 new positions and closed 372 in Q1 2020.
  • Raymond James & Associates's portfolio value fell 20% quarter-over-quarter to $63B.

Based on Raymond James & Associates's 13F filing for Q1 2020, filed 21 Apr 2020.